In fact, the therapeutic strategy using tumor/Gal has been extended to many types of CD1d+ tumor cells, including in our own studies, e.g., B16 melanoma, EL4 thymoma, WEHI3B leukemia, and J558 plasmacytoma. This evidence concerns the gene CD1D and neoplasm.